Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/22706
Title: Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy
Authors: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.
0000-0002-3425-0740
Özkan, Hasan Atilla
Hakyemez, Bahattin
Özkalemkaş, Fahir
Ali, Rıdvan
Özkocaman, Vildan
Özçelik, Tülay
Taşkapılıoğlu, Özlem
Altundal, Yıldız
Tunalı, Ayfer
X-3647-2018
AAI-2318-2021
AAG-8495-2021
AAH-1854-2021
9250698600
6602527239
6601912387
7201813027
6603145040
7005424333
23037226400
15080726300
6602797853
Keywords: Neurosciences & neurology
Radiology, nuclear medicine & medical imaging
Tumor lysis syndrome
Reversible posterior leukoencephalopathy syndrome
MRI
Chemotherapy
Leukemia
Lymphoma
Vasospasm
Patient
Combination chemotherapy
Encephalopathy syndrome
Issue Date: 2006
Publisher: Springer
Citation: Özkan, A. vd. (2006). ''Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy''. Neuroradiology, 48(12), 887-892.
Abstract: Introduction Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently described clinical and radiological entity comprising headache, seizures, altered level of consciousness and visual disturbances in association with transient posterior cerebral white-matter abnormalities. Method We report a young woman with Burkitt's lymphoma who developed RPLS after combined chemotherapy administered during the tumor lysis syndrome. Results The symptoms in this patient fitted well with those of RPLS; they included abrupt alterations in mental status, seizures, headache, visual changes and characteristic neuroradiological findings. She was given further combination chemotherapy without any neurological complications, at which time she had already recovered from both RPLS and tumor lysis syndrome. Conclusion Although many etiological factors have been reported in the development of RPLS, the underlying mechanism is not yet well understood. With prompt and appropriate management, RPLS is usually reversible, and chemotherapy can be continued after complete recovery from RPLS. We suggest that tumor lysis syndrome should be considered as a contributory factor to the development of RPLS in patients for whom treatment with combined chemotherapy for hematological malignancies is planned.
URI: https://doi.org/10.1007/s00234-006-0142-8
https://link.springer.com/article/10.1007/s00234-006-0142-8
http://hdl.handle.net/11452/22706
ISSN: 0028-3940
1432-1920
Appears in Collections:Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.